Evaxion Biotech (EVAX) Price & Analysis

Compare

384 Followers

EVAX Stock Chart & Stats

$6.21

-$0.02(-2.40%)

At close: Jan 08 4:00 PM EST

$6.21

-$0.02(-2.40%)

Day’s Range― - ―

52-Week Range$1.20 - $12.15

Previous CloseN/A

Volume99.85K

Average Volume (3M)119.79K

Market Cap

$40.74M

Enterprise ValueN/A

Total Cash (Recent Filing)$10.57M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Apr 07, 2026

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding6,316,572

10 Day Avg. Volume115,375

30 Day Avg. Volume119,786

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)-54.94

Price to Sales (P/S)27.14

P/FCF Ratio-7.01

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$12.33

Price Target Upside98.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Collaborations And Milestone PaymentsMerck exercised its option on a preclinical stage infectious disease vaccine candidate, resulting in a cash payment of $7.5MN to Evaxion and eligibility for milestone payments with a potential value of up to $592MN.

Innovative Vaccine DevelopmentThe AI-Immunology platform shows promise in discovering novel tumor neoantigens, potentially leading to innovative cancer vaccines.

Strategic PartnershipsEvaxion is well positioned to attract strategic partnerships due to its platform's ability to identify novel tumor antigens from complex genomic data.

Bears Say

Business Model RisksThe business model focused on developing vaccines through Phase 1/2 trials and then partnering or out-licensing the assets poses a valuation challenge, as the model is royalty-based and excludes milestone revenue.

Operational And Strategic RisksRisks for Evaxion include partnership, technology, clinical, regulatory, commercial, legal, intellectual property, and competition challenges.

Evaxion Biotech News

Evaxion Biotech presents new data for EVX-04

Evaxion A/S announces new data demonstrating that its AML vaccine candidate, EVX-04, triggers strong specific T-cell responses and...

6d ago

EVAX

Evaxion Biotech files to sell 38.45M ordinary shares for holders

08:46 EST Evaxion Biotech (EVAX) files to sell 38.45M ordinary shares for holders Published first on TheFly –...

22d ago

EVAX

Evaxion Biotech announces data for CMV vaccine program EVX-V1

Evaxion is successfully advancing its novel multi-component cytomegalovirus, CMV, vaccine program, EVX-V1, with new data demonstrating protective effects...

24d ago

EVAX

Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million

Evaxion Biotech ( ($EVAX) ) has issued an update. On December 10, 2025, Evaxion Biotech A/S filed a...

3d ago

EVAX

Evaxion Biotech: Innovative AI-Immunology Platform and Strategic Growth Potential Justify Buy Rating

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Evaxion Biotech, retaining the price target of...

4d ago

EVAX

Evaxion Unveils Promising Data for AML Vaccine at ASH Meeting

Evaxion Biotech ( ($EVAX) ) has issued an announcement. On December 6, 2025, Evaxion A/S presented new data...

6d ago

EVAX

Evaxion Reports Positive Data for CMV Vaccine Program

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 20, 2025, Evaxion A/S announced positive data...

23d ago

EVAX

Evaxion Biotech Increases Share Capital Following Warrant Exercise

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 4, 2025, Evaxion Biotech announced a share...

25d ago

EVAX

Evaxion A/S Announces 2026 Financial Calendar

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 12, 2025, Evaxion A/S announced its financial...

1M ago

EVAX

Evaxion Biotech’s Promising Future: Strategic Partnerships and Key Catalysts Drive Growth Potential

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Evaxion Biotech, retaining the price target of $10.00....

1M ago

EVAX

Evaxion Biotech’s Earnings Call Highlights Strategic Growth

Evaxion Biotech A/S Adr (($EVAX)) has held its Q3 earnings call. Read on for the main highlights of...

1M ago

EVAX

Evaxion Unveils New Immune Data for AI-Designed Cancer Vaccine

An update from Evaxion Biotech ( ($EVAX) ) is now available. On November 7, 2025, Evaxion A/S announced...

1M ago

EVAX

Evaxion Biotech Reports Strong Q3 2025 Results

Evaxion Biotech A/S Adr ( ($EVAX) ) has released its Q3 earnings. Here is a breakdown of the...

1M ago

EVAX

Evaxion Biotech reports Q3 EPS 1c vs (4c) last year

Reports Q3 revenue $7.492M, consensus $2.5M. “We are really pleased with our achievements in recent months which have...

1M ago

EVAX

EVAX FAQ

What was Evaxion Biotech A/S Adr’s price range in the past 12 months?

Evaxion Biotech A/S Adr lowest stock price was $1.20 and its highest was $12.15 in the past 12 months.

What is Evaxion Biotech A/S Adr’s market cap?

Evaxion Biotech A/S Adr’s market cap is $40.74M.

When is Evaxion Biotech A/S Adr’s upcoming earnings report date?

Evaxion Biotech A/S Adr’s upcoming earnings report date is Apr 07, 2026 which is in 114 days.

How were Evaxion Biotech A/S Adr’s earnings last quarter?

Evaxion Biotech A/S Adr released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.02.

Is Evaxion Biotech A/S Adr overvalued?

According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Evaxion Biotech A/S Adr pay dividends?

Evaxion Biotech A/S Adr does not currently pay dividends.

What is Evaxion Biotech A/S Adr’s EPS estimate?

Evaxion Biotech A/S Adr’s EPS estimate is -0.01.

How many shares outstanding does Evaxion Biotech A/S Adr have?

Evaxion Biotech A/S Adr has 6,316,572 shares outstanding.

What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?

Evaxion Biotech A/S Adr reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10.601%.

Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?

Currently, no hedge funds are holding shares in EVAX

Evaxion Biotech Stock Smart Score

Neutral

Company Description

Evaxion Biotech A/S Adr

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Evaxion Biotech (EVAX) Earnings & Revenues

Historic Earnings Reports

EVAX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial performance and significant advancements in R&D, including a transformative deal with MSD and promising clinical data for EVX-01. However, market uncertainties and extended evaluation periods for deals, like EVX-B2, present challenges. Overall, the achievements and financial stability significantly outweigh the challenges.View all EVAX earnings summaries

EVAX Stock 12 Month Forecast

Average Price Target

$12.33

▲(98.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.44,6.252307692307692,7.064615384615385,7.876923076923077,8.689230769230768,9.501538461538463,10.313846153846153,11.126153846153844,11.938461538461539,12.75076923076923,13.563076923076924,14.375384615384615,15.187692307692306,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.44,5.970000000000001,6.5,7.03,7.5600000000000005,8.09,8.620000000000001,9.15,9.68,10.21,10.740000000000002,11.27,11.8,{"y":12.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.44,5.790769230769231,6.141538461538461,6.492307692307692,6.843076923076923,7.193846153846154,7.544615384615385,7.895384615384615,8.246153846153845,8.596923076923076,8.947692307692307,9.298461538461538,9.649230769230769,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >